South San Francisco-based Denali Therapeutics Inc.'s dosing of the first patient in a phase Ib study with DNL-201 for Parkinson's disease (PD) brought renewed attention to the affliction and to the race with Glaxosmithkline plc (GSK), of London, in the development of leucine-rich repeat kinase 2 (LRRK2) inhibitors.